- You can view the full Vertex Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.
Jana Partners are placing three members on Tiffany's board.